|Dr. Dale R. Pfost Ph.D.||Chairman & CEO||192k||N/A||1957|
|Dr. Adi Mor George Ph.D.||Co-Founder, Chief Scientific Officer & Exec. Director||480k||N/A||1982|
|Mr. Donald R. Marvin MBA||CFO, Exec. VP & COO||94k||N/A||1953|
|Barbara Lindheim||Consulting VP of Investor & PR, Strategic Communications||N/A||N/A||N/A|
|Dr. David M. Weiner M.D.||Interim Chief Medical Officer||N/A||N/A||1965|
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.